Epstein-Barr virus-driven gene therapy for EBV-related lymphomas

Area of Science:

• Oncology
• Virology
• Gene Therapy

Background:

• Epstein-Barr virus (EBV) is linked to fatal B-cell lymphomas in immunosuppressed individuals.
• Targeting specific viral genes in cancer cells offers a potential strategy for selective gene therapy.
• The transcription factor EBNA2 is expressed in EBV-infected malignant cells.

Purpose of the Study:

• To investigate the selective targeting of EBV-related lymphoma cells using an EBNA2-responsive promoter to drive suicide gene expression.
• To evaluate the efficacy of this gene therapy approach in vitro and in vivo.

Main Methods:

• Utilized an EBV-specific promoter (BamC) to regulate a hygromycin-thymidine kinase fusion suicide gene.
• Tested ganciclovir sensitivity in cells expressing EBNA2.
• Assessed tumor regression in SCID mice bearing established B-cell lymphomas.

Main Results:

• Cells expressing EBNA2 showed selectively enhanced sensitivity to ganciclovir.
• Complete macroscopic regression of B-cell lymphomas was observed in treated SCID mice.
• Demonstrated in vitro and in vivo proof-of-concept for the targeted gene therapy model.

Conclusions:

• Exploiting the molecular basis of EBV-driven lymphomagenesis can enhance gene therapy specificity.
• This EBNA2-targeted suicide gene therapy shows significant potential for treating EBV-related lymphomas.
• The findings support a novel strategy for virus-regulated cancer gene therapy.